Nifty
:
23587.50
Sensex
:
78041.59
-364.20 (-1.52%)
-1176.46 (-1.49%)
Nifty
Sensex
:
:
23587.50
78041.59
-364.20 (-1.52%)
-1176.46 (-1.49%)

Cipla Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 500087 | NSE: CIPLA

NSE BSE
1472.05
20-Dec-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1506.55
  •  1506.60
  •  1469.05
  •  1506.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2196991
  •  32632.90
  •  1702.05
  •  1231.85

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,18,917.13
  • 26.57
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,18,157.88
  • 0.88%
  • 4.19

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 30.92%
  • 0.48%
  • 14.16%
  • FII
  • DII
  • Others
  • 28.8%
  • 22.36%
  • 3.28%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.55
  • 8.51
  • 5.80

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.27
  • 14.61
  • 6.87

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.08
  • 20.93
  • 17.69

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.36
  • 30.42
  • 30.25

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.62
  • 3.83
  • 4.02

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.03
  • 16.00
  • 16.47

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
51.05
58.22
64.7
65.81
P/E Ratio
29.21
25.61
23.05
22.66
Revenue
25447
27469
30128
31850
EBITDA
6291
6910
7645
7795
Net Income
4122
4647
5177
5410
ROA
13.3
13.5
13.3
12.5
P/Bk Ratio
4.51
3.97
3.48
3.11
ROE
16.45
16.27
15.78
14.22
FCFF
3192.03
3462.12
3809.98
5129.79
FCFF Yield
2.76
3
3.3
4.44

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
7,051.02
6,678.15
5.58%
6,693.94
6,328.89
5.77%
6,163.24
5,739.30
7.39%
6,603.81
5,810.09
13.66%
Expenses
5,165.43
4,944.40
4.47%
4,978.14
4,834.98
2.96%
4,847.38
4,565.56
6.17%
4,856.28
4,402.54
10.31%
EBITDA
1,885.59
1,733.75
8.76%
1,715.80
1,493.91
14.85%
1,315.86
1,173.74
12.11%
1,747.53
1,407.55
24.15%
EBIDTM
26.74%
25.96%
25.63%
23.60%
21.35%
20.45%
26.46%
24.23%
Other Income
190.61
176.32
8.10%
160.19
136.29
17.54%
249.33
134.63
85.20%
184.63
114.44
61.33%
Interest
15.40
25.80
-40.31%
17.95
16.39
9.52%
17.59
34.36
-48.81%
30.10
31.82
-5.41%
Depreciation
271.74
290.04
-6.31%
246.68
239.21
3.12%
288.34
346.22
-16.72%
233.43
272.11
-14.21%
PBT
1,789.06
1,594.23
12.22%
1,611.36
1,374.60
17.22%
1,259.26
745.37
68.94%
1,473.81
1,218.06
21.00%
Tax
483.04
438.41
10.18%
435.07
378.02
15.09%
324.86
222.25
46.17%
405.30
410.01
-1.15%
PAT
1,306.02
1,155.82
13.00%
1,176.29
996.58
18.03%
934.40
523.12
78.62%
1,068.51
808.05
32.23%
PATM
18.52%
17.31%
17.57%
15.75%
15.16%
9.11%
16.18%
13.91%
EPS
16.13
14.01
15.13%
14.58
12.33
18.25%
11.63
6.51
78.65%
13.08
9.92
31.85%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
26,512.01
25,774.09
22,753.12
21,763.34
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
Net Sales Growth
7.96%
13.28%
4.55%
13.59%
11.84%
4.70%
7.96%
5.29%
5.88%
19.83%
 
Cost Of Goods Sold
8,745.54
8,819.57
8,252.28
8,495.60
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
Gross Profit
17,766.47
16,954.52
14,500.84
13,267.74
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
GP Margin
67.01%
65.78%
63.73%
60.96%
61.63%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
Total Expenditure
19,847.23
19,483.04
17,762.83
17,251.38
14,910.94
13,951.18
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
Power & Fuel Cost
-
364.84
353.61
331.03
308.26
327.43
335.11
298.82
251.73
245.92
228.28
% Of Sales
-
1.42%
1.55%
1.52%
1.61%
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
Employee Cost
-
4,310.04
3,830.08
3,529.91
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
% Of Sales
-
16.72%
16.83%
16.22%
16.97%
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
Manufacturing Exp.
-
1,779.35
1,589.90
1,453.22
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
1,023.49
737.11
% Of Sales
-
6.90%
6.99%
6.68%
6.30%
8.01%
7.85%
8.05%
8.29%
7.53%
6.50%
General & Admin Exp.
-
1,673.94
1,423.23
1,206.07
986.01
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
% Of Sales
-
6.49%
6.26%
5.54%
5.15%
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
Selling & Distn. Exp.
-
1,724.97
1,694.30
1,670.00
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
% Of Sales
-
6.69%
7.45%
7.67%
6.78%
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
Miscellaneous Exp.
-
810.33
619.43
565.55
508.00
692.12
855.40
968.98
645.54
657.29
738.87
% Of Sales
-
3.14%
2.72%
2.60%
2.65%
4.04%
5.23%
6.39%
4.48%
4.83%
4.39%
EBITDA
6,664.78
6,291.05
4,990.29
4,511.96
4,248.65
3,180.81
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
EBITDA Margin
25.14%
24.41%
21.93%
20.73%
22.18%
18.57%
17.53%
16.19%
17.20%
18.24%
19.05%
Other Income
784.76
746.57
512.13
321.73
269.77
369.38
476.57
357.65
228.69
208.21
165.55
Interest
81.04
89.88
109.54
106.35
160.70
197.36
168.43
114.23
159.38
206.63
168.29
Depreciation
1,040.19
1,051.02
1,172.11
1,051.95
1,067.66
1,174.65
1,097.15
949.83
1,322.93
754.22
504.71
PBT
6,133.49
5,896.72
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
Tax
1,648.27
1,546.59
1,202.86
933.80
888.76
631.20
569.53
250.11
179.76
331.59
400.03
Tax Rate
26.87%
27.12%
29.79%
26.73%
27.01%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
PAT
4,485.22
4,123.14
2,804.51
2,529.57
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
PAT before Minority Interest
4,479.58
4,155.31
2,835.49
2,559.47
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
Minority Interest
-5.64
-32.17
-30.98
-29.90
16.36
47.00
35.26
-6.04
-29.03
-23.43
-48.15
PAT Margin
16.92%
16.00%
12.33%
11.62%
12.62%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
PAT Growth
28.75%
47.02%
10.87%
4.63%
51.67%
3.18%
9.31%
39.46%
-26.14%
13.76%
 
EPS
55.65
51.16
34.80
31.39
30.00
19.78
19.17
17.54
12.57
17.02
14.97

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
26,706.43
23,407.78
20,841.69
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
Share Capital
161.47
161.43
161.36
161.29
161.25
161.14
161.02
160.90
160.68
160.59
Total Reserves
26,458.42
23,184.53
20,636.35
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
Non-Current Liabilities
81.92
183.53
621.70
1,660.47
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
Secured Loans
0.00
332.46
376.20
355.32
304.74
47.70
0.00
0.00
207.00
287.09
Unsecured Loans
0.00
-332.46
40.04
847.43
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
Long Term Provisions
129.26
102.16
100.22
116.17
133.27
121.41
137.92
140.52
144.68
1,783.17
Current Liabilities
5,245.77
5,033.27
4,912.87
4,591.14
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
Trade Payables
2,473.98
2,534.52
2,508.10
2,066.82
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
Other Current Liabilities
890.98
1,007.60
769.81
1,093.21
706.65
541.86
647.04
908.95
1,006.14
654.55
Short Term Borrowings
247.02
187.90
393.34
334.73
447.15
486.16
435.87
467.23
4,969.67
1,392.48
Short Term Provisions
1,633.79
1,303.25
1,241.62
1,096.38
957.53
795.50
630.19
426.43
324.42
382.04
Total Liabilities
32,130.02
28,930.34
26,651.95
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
Net Block
9,493.61
9,100.65
9,621.91
9,393.77
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
Gross Block
18,161.28
17,204.76
16,968.35
15,647.05
14,913.62
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
Accumulated Depreciation
8,574.10
7,994.72
7,310.84
6,216.82
5,309.30
4,233.78
3,010.87
1,609.71
799.30
2,731.91
Non Current Assets
12,688.61
11,731.79
11,924.75
11,656.17
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
Capital Work in Progress
1,152.72
1,093.30
766.18
968.89
824.53
676.18
981.33
1,682.98
2,060.87
580.90
Non Current Investment
642.21
572.52
355.63
545.43
578.80
490.20
157.66
137.36
176.35
249.76
Long Term Loans & Adv.
838.53
845.11
736.39
645.57
677.08
455.57
514.96
543.67
426.18
1,860.29
Other Non Current Assets
447.93
60.38
383.22
102.51
77.61
166.82
255.71
210.06
176.54
168.88
Current Assets
19,392.45
16,805.06
14,710.83
13,181.03
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
Current Investments
4,807.01
3,089.86
2,194.97
2,286.37
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
Inventories
5,237.95
5,156.43
5,350.24
4,669.18
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
Sundry Debtors
4,770.66
4,057.00
3,424.44
3,445.68
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
Cash & Bank
874.97
1,564.62
1,928.48
1,401.23
1,003.91
618.81
965.61
638.27
871.40
564.26
Other Current Assets
3,701.86
373.99
305.56
347.54
1,416.84
1,566.48
1,599.13
1,226.01
1,223.17
858.67
Short Term Loans & Adv.
3,134.22
2,563.16
1,507.14
1,031.03
974.82
1,150.95
1,118.93
807.84
780.03
713.07
Net Current Assets
14,146.68
11,771.79
9,797.96
8,589.89
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
Total Assets
32,081.06
28,536.85
26,635.58
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
4,133.91
3,237.65
3,325.90
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
PBT
5,896.72
4,220.77
3,675.39
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
Adjustment
640.77
878.19
967.47
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
Changes in Working Capital
-806.10
-559.42
-177.46
371.66
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
Cash after chg. in Working capital
5,731.39
4,539.54
4,465.40
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,597.48
-1,301.89
-1,139.50
-1,037.43
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,988.03
-2,388.51
-1,871.88
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
Net Fixed Assets
-373.49
-600.42
-321.93
-437.48
-450.41
-173.16
-509.84
-889.04
1,487.25
-534.38
Net Investments
-1,884.41
-935.67
-1,124.06
-2,533.43
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
Others
-730.13
-852.42
-425.89
583.73
1,993.60
-255.78
6.92
-391.07
-6,174.87
427.20
Cash from Financing Activity
-1,200.43
-958.29
-1,599.79
-1,239.51
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
Net Cash Inflow / Outflow
-54.55
-109.15
-145.77
128.51
223.67
-326.26
223.27
-254.13
322.24
397.06
Opening Cash & Equivalents
561.33
658.11
790.43
649.13
508.36
853.47
610.35
858.15
545.84
175.76
Closing Cash & Equivalent
512.34
561.33
658.11
790.43
742.38
508.36
853.46
610.35
858.15
564.26

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
329.72
289.24
257.78
226.73
194.85
185.62
175.92
155.15
142.23
133.38
ROA
13.59%
10.19%
9.94%
9.95%
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
ROE
16.63%
12.85%
13.10%
14.13%
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
ROCE
22.77%
18.19%
17.24%
17.85%
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
Fixed Asset Turnover
2.00
1.81
1.82
1.85
1.89
1.79
1.25
1.36
1.40
1.26
Receivable days
45.49
44.13
42.19
47.44
54.10
55.36
68.17
61.60
57.62
57.94
Inventory Days
53.56
61.98
61.53
58.49
56.12
61.13
90.71
91.41
100.43
106.36
Payable days
103.64
111.52
98.28
107.95
128.84
59.02
57.37
46.96
51.51
52.17
Cash Conversion Cycle
-4.58
-5.41
5.44
-2.02
-18.63
57.47
101.50
106.05
106.55
112.14
Total Debt/Equity
0.01
0.02
0.04
0.10
0.18
0.29
0.29
0.33
0.46
0.16
Interest Cover
64.44
37.87
33.85
21.47
12.04
13.34
15.61
8.67
9.36
10.83

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Cipla secures approval for distribution, marketing of Afrezza Inhalation Powder in India
    13th Dec 2024, 12:39 PM

    This is the first and only noninjectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus

    Read More
  • USFDA concludes inspection at Cipla’s manufacturing facility in Bengaluru
    14th Nov 2024, 09:40 AM

    On conclusion of the inspection, the Company received 8 observations in Form 483

    Read More
  • Cipla’s consolidated net profit rises 13% in Q2FY25
    29th Oct 2024, 15:51 PM

    Consolidated total income of the company increased by 5.65% at Rs 7,241.63 crore for Q2FY25

    Read More
  • Cipla - Quarterly Results
    29th Oct 2024, 14:19 PM

    Read More
  • Cipla’s arm to acquire 6.9% stake held by Jiangsu Xidi Pharmaceuticals in China-based unit
    26th Sep 2024, 12:44 PM

    Upon completion of the transaction, Cipla Jiangsu will become a wholly owned step-down subsidiary of the Company

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.